Repligen Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Repligen (RGEN) PT Lowered to $940 at Truist Securities
April 29, 2025 4:03 PM EDTTruist Securities analyst Srikripa Devarakonda lowered the price target on Repligen (NASDAQ: RGEN) to $940.00 (from $975.00) while maintaining a Buy rating.
The analyst comments "While near-term investor focus remains on the Eylea tail, REGN continues to deliver growth on top/bottom line... More
Repligen (RGEN) PT Lowered to $914 at Jefferies
April 29, 2025 3:58 PM EDTJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.
The analyst comments "Bottom line: REGN entered Q1 w/ a fairly negative bias into the print given: 1) we were modeling Eylea to miss HERE given the issues w/ Good Days, its pt assistance... More
Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'
April 29, 2025 2:54 PM EDTJPMorgan analyst Rachel Vatnsdal lowered the price target on Repligen (NASDAQ: RGEN) to $190.00 (from $200.00) while maintaining a Overweight rating.
The analyst comments "Repligen (RGEN) reported a strong top-line and bottom-line 1Q beat while reiterating organic revenue growth for the year. Diving deeper, RGEN revenues of $169M came in above the Street of $164M, reflecting +11% organic growth y/y (vs. Street of +7.9% y/y), leading to adj. EPS of $0.39 (vs. Street of $0.34). RGEN raised its... More
